RedHill Biopharma Ltd. (RDHL)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$0.4928−1.44%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $4.4M
- Forward P/E
- 16.4
- 52-week range
- $0.465 – $2.14
- 52-week change
- −73.40%
- EPS (trailing)
- $0.00
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation.
Headquarters: Tel Aviv-Yafo, Israel · 13 employees · redhillbio.com